Assessing Alphatec Holdings (ATEC) Valuation After Q1 2026 Growth And New Bank Facility

Q1 results and new financing shift attention to Alphatec Holdings (ATEC)

Alphatec Holdings (ATEC) reported Q1 2026 surgical revenue growth of 17% and total revenue growth of 14% to US$192 million, along with a new bank facility that lowers interest expenses and extends debt maturities.

See our latest analysis for Alphatec Holdings.

Despite the Q1 update and refinancing, Alphatec Holdings’ share price is down 28% over the past month and 64% year to date, while the 1 year total shareholder return has declined 39%. This suggests recent momentum has weakened even as the business updates its outlook.

If this kind of volatility has you thinking about where else growth stories could emerge in healthcare, it may be worth scanning 40 healthcare AI stocks

So with revenue rising, refinancing in place and the share price sharply lower, is Alphatec starting to look mispriced, or is the current valuation already reflecting the growth that management is targeting from here?

Most Popular Narrative: 56.8% Undervalued

At a last close of $7.48 versus a narrative fair value of $17.33, Alphatec Holdings is framed as materially undervalued using a discounted cash flow approach.

Expanding surgeon adoption, strong same-store sales growth, and increasing procedural volume signal Alphatec's ability to leverage the aging population and rising prevalence of spinal conditions, driving substantial and durable revenue growth.

Read the complete narrative. Read the complete narrative.

Want to see what is sitting behind that valuation gap? The narrative leans heavily on faster revenue growth, margin expansion, and a richer future earnings multiple. The specific forecasts and profit assumptions do a lot of the heavy lifting in that $17.33 figure.

Result: Fair Value of $17.33 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that upside story still depends on key risks, including ongoing operating losses and intense competition in spine devices that could pressure margins and growth expectations.

Find out about the key risks to this Alphatec Holdings narrative.

Next Steps

Seeing both optimism and concern in this story is normal, and the best way forward is to move quickly, examine the full picture, and weigh the trade offs yourself using the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Alphatec has caught your interest, do not stop there. Broaden your watchlist now and give yourself more options before the next big move.

• Target potential upside by scanning companies flagged as 47 high quality undervalued stocks that pair appealing prices with solid fundamentals.
• Strengthen your income focus by reviewing stocks in the 10 dividend fortresses that aim for yields above 5% while prioritising stability.
• Prioritise resilience by checking out companies in the 62 resilient stocks with low risk scores that score well on balance sheet strength and risk metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com